Apeldoorn

• DISTINCT: inDividual, targeted thrombosIS prophylaxis versus the standard ‘one size fits all’ approach in patients undergoing Total hIp or t … Recruiting
  2023-510186-98-00 6 2024-10-23 Venous thromboembolism
• Remimazolam versus Midazolam for sedation during upper GI endoscopy: a randomized controlled trial Recruiting
  2024-516432-94-00 6 2024-10-21 N/A
• Tranexamic acid to prevent OpeRation in Chronic subdural Hematoma (TORCH) Recruiting
  2024-514927-40-02 11 2024-10-01 Chronic Subdural Hematoma
• HOVON 170 DLBCL: ANTICIPATE: Prevention of ANThracycline-Induced Cardiac dysfunction by dexrazoxane In PATients with diffusE large B-cell ly … Recruiting
  2023-505377-32-00 5 2024-08-15 Diffuse large B-cell lymphoma (DLBCL)
• OPTIMISE: Optimized Immunosuppression for Corneal Transplantation: a multi-centre randomized controlled clinical trial Recruiting
  2022-500109-41-00 6 2024-07-29 Corneal transplantation, Descemet's Membrane Endothelial Keratoplasty
• FeAsiBility of a treatment free interval in newly diagnosed mUltiple myeLOma patients treated with DaratumUmab-Lenalidomide-DexamethaSone – … Recruiting
  2023-508586-33-00 5 2024-05-14 multiple myeloma
• Metamizole as pain treatment in patients with chronic pancreatitis, a multicenter, randomized, double-blind, placebo-controlled, superiority … Recruiting
  2023-504143-14-00 6 2024-05-02 Chronic pancreatitis
• VulVaccin study Recruiting
  2023-506792-94-00 11 2024-03-04 Vulvar High-Grade Squamous Intraepithelial Lesion (vHSIL)
• Treatment of Menière's disease with intratympanic methylprednisolone (PREDMEN trial) Recruiting
  2023-503340-13-00 5 2023-10-05 Menière's disease
• The RiCOTTA study: Rifampicin Combination Therapy versus Targeted Antibiotic Monotherapy for Infected Joint Prostheses Caused by Staphylococ … Recruiting
  2022-501620-26-00 6 2023-05-15 prosthetic joint infection
• Renal Lifecycle Trial: A Randomized Controlled Clinical Trial to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in … Recruiting
  2023-508389-13-00 5 2022-11-08 Combined endpoint of all-cause mortality, kidney failure, and hospital
• A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination … Recruiting
  2023-503442-30-00 5 2022-10-14 Multiple Myeloma
• The efficacy of the addition of TRAstuzumab and Pertuzumab to neoadjuvant chemoradiation: a randomized multi-center study in resectable HER2 … Recruiting
  2024-513797-22-00 5 2022-03-09 HER2 positive esophageal adenocarcinoma
• Selatogrel Outcome Study in Suspected Acute Myocardial Infarction Recruiting
  2023-505438-85-00 5 2022-01-12 Acute myocardial infarction (AMI)
• Multicentre, open-label, randomized, controlled, parallel arms clinical trial of induction chemotherapy followed by chemoradiotherapy versus … Recruiting
  2024-512526-28-00 5 2020-10-28 Locally recurrent rectal cancer
• DRUP trial Recruiting
  2023-509152-33-00 4 2016-07-25 Advanced solid tumor
• A Study of Lepodisiran (LY3819469) in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) Ended recruitment
  2023-509190-23-00 5 2024-09-03 Atherosclerotic Cardiovascular Disease Elevated lp(a)
• TGF‐β And PDL‐1 inhibition with Bintrafusp alfa in Esophageal Squamous Cell carcinoma combined with chemoradiation TheRapY (TAPESTRY) Ended recruitment
  2023-503312-32-00 4 2024-06-24 Esophageal squamous cell carcinoma
• A Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascu … Ended recruitment
  2022-502781-24-01 5 2024-06-05 ASCVD - Atherosclerotic Cardiovascular Disease
• The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-OUTCOMES) Ended recruitment
  2023-508630-34-00 5 2024-05-28 Overweight
• Aspirin to prevent cardiovascular events in patients with pneumonia or influenza Ended recruitment
  2023-504553-12-01 6 2023-12-27 Influenza
• LIBREXIA-AF A Phase 3 Active-controlled Study of Milvexian for Prevention of Cardioembolic Events in Participants with Atrial Fibrillation Ended recruitment
  2022-501419-15-00 5 2023-08-23 Atrial Fibrillation
• A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants with Severe Hypertriglyceridemia (SHTG) Ended recruitment
  2022-501999-26-00 5 2023-07-12 Severe Hypertriglyceridemia (SHTG)
• OCEAN(a)-Outcomes – Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction – Outcomes trial Ended recruitment
  2022-501608-85-00 5 2023-05-09 Cardiovascular disease (atherosclerotic cardiovascular disease (ASCVD)

Showing 25–48 of 67 trials